Remora Capital

Remora operates as a company builder rather than a conventional venture fund. It originates companies from breakthrough science, de-risks them through early development, and creates individual portfolio entities — a model that separates platform economics from single-asset risk. The June 2024 acquisition of its portfolio company Fastox by AbbVie illustrates the builder-to-exit pathway.

The firm focuses on four modalities: immunotherapy, vectorized therapies that deliver targeted drug payloads, cell and gene therapy, and an emerging regenerative and aesthetics vertical. The regenerative platform targets healthy-ageing applications, while the immunotherapy work prioritizes multifunctional immune modulators for cancer and immune disease.

Remora's public positioning describes a company-builder model that creates and advances its own portfolio of biotherapy companies. The firm invites qualified investors to gain exposure to that diversified portfolio, which implies a central holding entity rather than a third-party fund-of-funds or venture capital allocation program.

Remora does not name principals, managing partners, or investment committee members on its website. No executive names appear in the firm's own published materials, and no LinkedIn profile for the firm was located in the research record. The operator set behind the builder model remains undisclosed as of this profile.

Remora is physically embedded at Biopôle, the life-sciences innovation campus in Lausanne, Switzerland. In December 2025 the firm publicly emphasized its position inside the cluster, which provides access to scientific talent, shared research infrastructure, and the broader European biotech network that feeds its company-creation pipeline.